



Genvoya[®] (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) – Expanded indication

- On September 26, 2017, the FDA announced the approval of Gilead Sciences' [Genvoya \(elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide \[TAF\]\)](#) tablets, indicated as a complete regimen for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA < 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya.
 - Previously, Genvoya was indicated in adults and pediatric patients 12 years of age and older weighing at least 35 kg.
- Genvoya is a four-drug combination of an HIV-1 integrase strand transfer inhibitor (elvitegravir); a CYP3A inhibitor (cobicistat); and two HIV-1 nucleoside analog reverse transcriptase inhibitors (emtricitabine and TAF).
- The approval of the expanded indication for Genvoya was based on an efficacy, safety, and pharmacokinetic open-label study in 23 virologically-suppressed children between the ages of 6 to less than 12 years weighing at least 25 kg.
 - After switching to Genvoya, 100% of patients remained suppressed (HIV-1 RNA < 50 copies/mL) at week 24.
 - All patients maintained CD4+ cell counts > 400 cells/mm³.
- Genvoya carries a boxed warning for post treatment acute exacerbation of hepatitis B.
- The recommended dosage of Genvoya is one tablet taken orally once daily with food in adults and pediatric patients with a body weight of at least 25 kg.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.